ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits.
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2...
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1...
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy®
主要亚太国家/地区的授权合作伙伴已向监管机构申请批准 2 毫克剂量的 neffy（肾上腺素鼻喷雾剂）...
ARSファーマシューティカルズ (ARS Pharmaceuticals)、neffy®の中国、日本、オーストラリアでの承認申請を発表
アジア太平洋地域の主要国におけるライセンスパートナーが、neffy (エピネフリン点鼻スプレー) 2mgの承認を規制当局に申請した...
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies...
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal...
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA;...
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it.
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK’s global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of...
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1...
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
EURneffy offers adults and children (≥30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30...